Clémence B. D. L. P.
- Country
- France
- Department
- Medical oncology
Research Overview
- Phase II Study of Ficerafusp Alfa and Nivolumab in Patients with Platinum-Refractory Head and Neck Squamous Cell Carcinoma Progressing Within 6 Months of Multimodal Therapy
- A randomized, open-label, multicenter, Phase 3 trial of ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma(HNSCC)
Data & Insights
Has run more than one trial at 8 of 49 partner sites.
Specializations
Thoracic Oncology
Clémence BRAC DE LA PERRIERE is involved in clinical research in non-small cell lung cancer and small cell lung cancer, with interest in both advanced disease and locally advanced settings. Her work also extends to molecularly defined lung cancer populations, including KRAS G12C mutation-positive and ROS1-positive disease.
- Metastatic non-small cell lung cancer
- Unresectable stage III non-small cell lung cancer
- PD-L1-high metastatic lung cancer
- Squamous and non-squamous histologies
Her clinical research landscape includes immunotherapy, targeted therapy, and combined modality treatment strategies in thoracic malignancies.
Breast Cancer
Her research activity includes multiple areas of breast cancer, especially HER2-positive, HER2-low, and hormone receptor-positive disease. She is also engaged in studies focused on early-stage and advanced breast cancer, including biomarker-defined populations.
- HER2-positive metastatic breast cancer
- HR-positive, HER2-negative early breast cancer
- PIK3CA-mutant advanced breast cancer
- Pretreated unresectable locally advanced breast cancer
Her therapeutic focus includes endocrine therapy, antibody-based treatment, and precision oncology approaches in breast malignancies.
Gynecologic Malignancies
Clémence BRAC DE LA PERRIERE is active in clinical trials for endometrial cancer, ovarian cancer, cervical cancer, and uterine leiomyosarcoma. Her portfolio includes both advanced disease and post-operative settings, with attention to molecularly selected patient groups.
- Advanced or recurrent endometrial cancer
- Ovarian epithelial cancer
- Locally advanced cervical cancer
- Metastatic leiomyosarcoma
Her therapeutic interests cover immunotherapy, maintenance strategies, and individualized treatment for gynecologic cancers.
Digestive and Biliary Cancers
Her clinical research includes biliary tract cancer, gastroesophageal adenocarcinoma, gastric cancer, and metastatic colorectal cancer. She is involved in studies addressing both resected and metastatic disease, with emphasis on systemic treatment selection.
- Biliary tract carcinoma
- Gastroesophageal adenocarcinoma
- Microsatellite stable metastatic colorectal cancer
- Non-metastatic gastric or esophageal adenocarcinoma
Her work in this area reflects a focus on immunotherapy combinations, perioperative management, and targeted treatment for gastrointestinal tumors.
Genitourinary and Molecularly Selected Solid Tumors
Her research also covers prostate cancer, bladder cancer, renal cell carcinoma, and other advanced solid tumors defined by actionable molecular alterations. This includes tumors with BRAF, NTRK, ALK, and ROS1 rearrangements.
- Metastatic castration-resistant prostate cancer
- Urinary bladder neoplasms
- Renal cell carcinoma
- Solid tumors with gene rearrangements
Her therapeutic interest includes radioligand therapy, androgen receptor pathway targeting, and biomarker-driven treatment for advanced malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.